Product Images Droxidopa

Droxidopa is a medication for which there is a report showing the mean change in dizziness over a period of 8 weeks during its double-blind treatment phase. The data is presented in a table where the baseline value is compared with the values obtained at weeks 1 to 8. The value of the mean change is equal to 35, but there is no further context or explanation provided to interpret this value.*

This is the description for a medication called Droxidopa Capsules. Each capsule contains 100 mg of droxidopa and comes in a child-resistant package. The recommended dosage can be found in the package insert. It should be stored at a temperature between 20°C to 25°C, with permitted excursions to 15°C to 30°C. The medication should be dispensed in a light-resistant container, and if the printed seal under the cap is broken or missing, it should not be used. This drug should be kept out of reach of children. The manufacturer is Cadila Healthcare Ltd located in Ahmedabad, India, and the product is distributed by Zydus Pharmaceuticals (USA) in Pennington, NJ.*

This is a description of a medication called droxidopa. Each capsule contains 200 mg of droxidopa. The usual dosage is provided in the package insert. The medication should be stored at 20°C to 25°C. It should be kept out of reach of children and dispensed in a tight, light-resistant container. The manufacturer is Cacila Healthcare Lid in Abmedabad, India, and it is distributed by Zydus Pharmaceuticals (USA) in Pennington, NJ.*

This is a prescription drug capsule manufactured in Abmedabad, India by Zydus Pharmaceuticals (USA) Inc. Each capsule contains 300 mg of droxidopa. This drug is stored at 20°C to 25°C (68°F to 77°F) within a tight, light-resistant container, with 90 capsules distributed. Please refer to the package insert for complete prescribing information.*